Tarsus Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies targeting diseases of the eye and infectious conditions in the United States; its lead commercialized product is XDEMVY (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment for Demodex blepharitis caused by Demodex mite infestation, as well as for associated meibomian gland disease; the company advances a pipeline of wholly owned lotilaner-based candidates, including TP-04 (lotilaner ophthalmic gel) for ocular rosacea, TP-05 for Lyme disease prophylaxis and community malaria reduction, and lotilaner active pharmaceutical ingredient for additional eye care and infectious disease prevention applications. Founded in 2016 and headquartered in Irvine, California, Tarsus operates primarily in the biotechnology sector with emphasis on eye care and parasitology-driven therapeutics for patients underserved by existing treatments. In recent developments, the company reports robust growth in XDEMVY net product sales, reaching $78.3 million in Q1 2025 (up 217% year-over-year), $118.7 million in Q3 2025 (up 147% year-over-year), and projecting $140-145 million for Q4 2025, supported by expanded payer coverage exceeding 90% of U.S. patients, sales force enhancements, and direct-to-consumer campaigns; Tarsus strengthened its balance sheet with a $135 million public equity offering in Q1 2025, bringing cash reserves to approximately $408 million, while planning Phase 2 initiation for TP-04 in ocular rosacea in H2 2025 and advancing studies for TP-05.
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease